Ryan Patrick Coll, Ph.D.
Department of Cancer Systems Imaging, Division of Diagnostic Imaging
Present Title & Affiliation
Primary Appointment
Instructor, Department of Cancer Systems Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Instructor, Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2021 | Texas A&M University, College Station, Texas, US, Chemistry, Ph.D |
| 2014 | Wake Forest University, Winston-Salem, North Carolina, US, Chemistry with Biochemistry, BS |
Postgraduate Training
| 2022-2024 | Postdoctoral Fellow, Antibody-Based Radionuclide Theranostics, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2021-2021 | Postdoctoral Fellow, Dirhodium and Ruthenium Complex Design for Biological and Electrocatalytic Applications, Texas A&M University, College Station, Texas |
Honors & Awards
| 2025 - Present | Top 2 Oral Presentation-Faculty Category, 3rd International Conference on Cancer Health Disparities |
| 2024 | Best Oral Presentation-Fellow/Post-Doc Category, 2nd International Conference on Cancer Health Disparities |
| 2024 | Trainee Travel Award, 2nd International Conference on Cancer Health Disparities |
| 2023 | Presentation Award, Metabolism in Cancer Symposium Poster Session, The University of Texas MD Anderson Cancer Center |
| 2023 | Second Place Travel Scholarship, Diagnostic Imaging Trainee Research Symposium, The University of Texas MD Anderson Cancer Center |
| 2023 | Student Travel Stipend, World Molecular Imaging Society |
| 2023 | iSRS 2023 Student/Postdoc Travel Award, Society of Radiopharmaceutical Sciences |
| 2021 | Leadership in Equity and Diversity Award, Texas A&M University College of Science |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2024. The Suitability of Zr-89 and Tb-161 as a Theranostic Pair as Evaluated through Ex Vivo Biodistribution and Nuclear Imaging Studies in Mouse Models. Poster. 13th Annual Metabolism in Cancer Symposium. Houston, Texas, US.
- 2024. Evaluating the therapeutic capability of a mucin 13 (MUC13)-directed antibody labeled with dual beta and Auger electron-emitting 161Tb. Poster. Diagnostic Imaging Trainee Research Symposium. Houston, Texas, US.
- 2024. Evaluating the Therapeutic Capability of a Mucin 13 (MUC13)-Directed Antibody Labeled with Dual Beta and Auger Electron-Emitting 161Tb. Poster. Cancer Systems Imaging Retreat and Symposium. Galveston, Texas, US.
- 2023. Optimizing routine production of [C-11]HCN for PET tracer development and clinical trials. Poster. 12th Annual Metabolism in Cancer Symposium. Houston, Texas, US.
- 2023. Evaluating the radionuclide theranostic potential of a MUC13-targeting antibody in colorectal cancer. Conference. Cancer Systems Imaging Retreat and Symposium. Galveston, Texas, US.
- 2023. Targeting the glycoprotein MUC13 for potential radionuclide theranostic development in colorectal cancer. Conference. Diagnostic Imaging Trainee Research Symposium. Houston, Texas, US.
- 2022. A study in targeting epithelial carcinomas using a 89Zr-radiolabeled anti-MUC13 antibody. Poster. Cancer Systems Imaging Retreat and Symposium. Galveston, Texas, US.
Regional Presentations
- 2025. Evaluation of mucin 13 expression as a target for radioimmunotherapy: One step closer to a radionuclide theranostic strategy for colorectal cancer. Conference. 3rd International Conference on Cancer Health Disparities. Mission, Texas, US.
- 2024. Glycoprotein-targeted radionuclide theranostic pair for CRC. Invited. Southwest Regional Meeting of the American Chemical Society. Waco, Texas, US.
- 2024. Assessment of Mucin 13 (MUC13) as an imaging target for guiding colorectal cancer treatment: A pathway towards theranostic development. Conference. 2nd International Conference on Cancer Health Disparities 2024. Mission, Texas, US.
National Presentations
- Evaluating the radionuclide theranostic potential of a MUC13-targeting antibody in colorectal cancer, International Symposium on Radiopharmaceutical Sciences. Poster. International Symposium on Radiopharmaceutical Sciences 2023. Honolulu, Hawaii, US.
- Evaluation of MUC13 as a potential theranostic target for colorectal cancer using radioimmuno-PET imaging in a cell line-derived xenograft mouse model, World Molecular Imaging Congress. Poster. World Molecular Imaging Congress 2022. Miami, Florida, US.
- Spectroscopic and photochemical studies of a rare thiolate-bridged Rh2(II,II) complex lacking a metal-metal bond and exhibiting reversible redox events. Conference. American Chemical Society Fall 2020 Virtual Meeting & Exposition 2020, US.
- Multi-dose 161Tb radioimmunotherapy for improved outcome in MUC13-expressing xenograft mouse models of colorectal cancer. Poster. World Molecular Imaging Congress 2025. Anchorage, Alaska, US.
International Presentations
- Mucin 13 (MUC13) as an imaging target for radioimmuno-PET: Towards development of a theranostic strategy for colorectal cancer treatment. Poster. 7th Theranostics World Congress 2024. Santiago, CL.
- Optimizing routine production of [C-11]HCN for PET tracer development and clinical trials. Poster. World Molecular Imaging Congress 2023. Prague, CZ.
- The suitability of 89Zr and 161Tb as a theranostic pair as evaluated through ex vivo biodistribution and nuclear imaging studies in mouse models. Poster. World Molecular Imaging Congress 2024. Montreal, CA.
Grant & Contract Support
| Date: | 2026 - 2031 |
| Title: | Cell Surface Mucin 13-targeted Radionuclide Theranostics for Colorectal Cancer |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | R01CA311463 |
| Date: | 2026 - 2028 |
| Title: | Spanning the d-block: bimetallic macrocyclic chelators to carry disparate theranostic radiometals |
| Funding Source: | NIH |
| Role: | Co-I |
| Date: | 2026 - 2028 |
| Title: | Improving radionuclide therapeutic efficacy through inhibition of pathways contributing to radioresistance |
| Funding Source: | NIH |
| Role: | Co-PI |
| Date: | 2025 - 2028 |
| Title: | MUC13 Targeted Theranostics for Colorectal Cancer |
| Funding Source: | CPRIT |
| Role: | Co-I |
| Date: | 2025 - 2026 |
| Title: | Improving Radionuclide Therapeutic Efficacy through Inhibition of Pathways Contributing to Radioresistance |
| Funding Source: | U Foundation |
| Role: | Co-I |
| ID: | N/A |
| Date: | 2025 - Present |
| Title: | Single-use Microfluidic Device for Radiopharmaceutical Production |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | R01EB034665 |
| Date: | 2024 - 2025 |
| Title: | Radionuclide Theranostic for BRAF-mutated CRC |
| Funding Source: | Colorectal Cancer Alliance |
| Role: | Co-I |
| Date: | 2020 - 2026 |
| Title: | CPRIT Recruitment – Established Investigator |
| Funding Source: | CPRIT |
| Role: | Co-I |
| ID: | RR200046 |
Selected Publications
Peer-Reviewed Articles
- Sharma S, Wen X, Wang J, Huang B, Hernandez D, Pham CD, Liu Z, Lin SJ, Yamaguchi A, Georgiou DK, Coll RP, Manning HC. Preclinical Fluorescence-Guided Imaging Leveraging Surrounding Sentinel Tumor Microenvironment Identifies High-Risk Premalignant Pancreatic Lesions. Clin Cancer Res, 2025. e-Pub 2025. PMID: 40853902.
- Yamaguchi A, Coll RP, Bae SW, Wang J, Ta RT, Huang B, Chauhan SC, Manning HC. Preclinical evaluation of a mucin-13 targeted radionuclide theranostic approach suitable for metastatic colorectal cancer. e-Pub 2024.
- Coll RP, Yamaguchi A, Wen X, Wang J, Delacerda J, Ta RT, Manning HC. The suitability of pairing 89Zr and 161Tb for antibody-based theranostic application. e-Pub 2024.
- Coll RP, Dunbar KR. Three Reversible Redox States of Thiolate-Bridged Dirhodium Complexes without Metal-Metal Bonds. J Am Chem Soc 142(38):16313-16323, 2020. e-Pub 2020. PMID: 32790995.
- Strangis SR, Paolillo V, Coll RP, Ta RT, Manning HC. Optimizing routine production of [C-11]HCN for PET tracer development and clinical trials.
Review Articles
- Coll RP, Bright SJ, Martinus DKJ, Georgiou DK, Sawakuchi GO, Manning HC. Alpha particle-emitting radiopharmaceuticals as cancer therapy: biological basis, current status, and future outlook for therapeutics discovery. Mol Imaging Biol 25:991-1019, 2023. e-Pub 2023. PMID: 37845582.
- Lin M, Coll RP, Cohen AS, Georgiou DK, Manning HC. PET oncological radiopharmaceuticals: current status and perspectives. Molecules 27:6790, 2022. e-Pub 2022. PMID: 36296381.
Abstracts
- Saha S, Coll RP, Fillman K, Pellois JP, Turro C, Dunbar KR. Photoreleasing caged molecules containing nitrile functionality from Ru(II) complexes of the bulky 6-phenyl-2,2’-bipyridine ligand. 253rd American Chemical Society National Meeting & Exposition, 2017. e-Pub 2017.
Patient Reviews
CV information above last modified September 11, 2025